Oshima Tsukasa, Ikutomi Masayasu, Shinohara Hiroki, Ishiwata Jumpei, Fukino Keiko, Amaki Toshihiro, Nakamura Fumitaka
Third Department of Internal Medicine, Teikyo University Chiba Medical Center.
Int Heart J. 2016 Sep 28;57(5):634-6. doi: 10.1536/ihj.16-100. Epub 2016 Sep 13.
Thrombotic microangiopathy (TMA) is a rare but lethal multisystem disease characterized by peripheral thrombocytopenia, microangiopathic hemolytic anemia, fever, and various stages of renal and neurological dysfunctions.(1,2)) The causes of TMA are mainly thrombotic thrombocytopenic purpura (TTP) or hemolytic-uremic syndrome (HUS), and cases of TMA related to myelodysplastic syndrome (MDS) are quite rare. Herein, we report a case of acute myocardial infarction (AMI) caused by TMA which is strongly suspected to have a relationship to MDS, and discuss the treatment of our patient who needed antiplatelet or anticoagulant therapy after AMI, while on the other hand, had pancytopenia and a bleeding event due to MDS.
